Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
• Six major study readouts expected across four programs in next 12 months • Preparing to launch pivotal studies for two DEE programs: EMERALD and EMBRAVE3 • Vormatrigine showing promising safety profile with no food effect • RADIANT study topline results expected by mid-2025 • Essential3 program for ulixacaltamide continuing despite interim analysis recommendation
Financial highlights for Q1 2025: • Net loss of $69.3M vs $39.6M in Q1 2024 • R&D expenses increased to $60.8M from $27.0M YoY • G&A expenses decreased to $13.9M from $15.3M YoY • 20.3M shares outstanding as of March 31, 2025
Praxis Precision Medicines (NASDAQ: PRAX) has announced a virtual investor event scheduled for May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT. The webinar will focus on the company's clinical programs in developmental and epileptic encephalopathies (DEEs).
The presentation will cover three key clinical studies:
- The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
- The EMERALD study evaluating relutrigine for broader DEEs
- The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE
The event will be hosted by the Praxis management team, with a replay available on the company's website for 90 days under the 'Events & Presentations' page.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two major investor conferences in April 2025.
The company will present a corporate overview at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 11:00 a.m. EDT, which will be available via webcast. Additionally, Praxis management will attend the Piper Sandler Spring Biopharma Symposium in Boston on April 17, 2025, offering one-on-one meeting opportunities.
Investors interested in meetings should contact their Needham or Piper Sandler representatives. Webcast replays will be accessible through the company's website's 'Events & Presentations' page for 90 days.
Praxis Precision Medicines (Nasdaq: PRAX) has announced the granting of restricted stock unit awards to four new non-executive employees. The Compensation Committee of Praxis' Board of Directors approved these grants on April 1, 2025, under the company's 2024 Inducement Plan.
The awards cover an aggregate of 8,763 shares of common stock and will vest in four equal annual installments, contingent upon continued employment. These equity awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation at the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5-9, 2025, in San Diego. The company will present data from four late-stage programs focused on epilepsy and movement disorders.
The presentations include updates on the vormatrigine ENERGY program and newly initiated clinical trials across the U.S., Europe, and Latin America. Praxis will host an In-Booth Speaker Showcase featuring experts in CNS disorders at booth #2113.
Key presentations include:
- Two posters on Essential Tremor management and clinical trial characteristics for ulixacaltamide
- An observational study on epilepsy monitoring (EMPOWER)
- Updates from the Phase 1 trial of vormatrigine
Praxis Precision Medicines (NASDAQ: PRAX) has announced equity grants to six new non-executive employees under its 2024 Inducement Plan. The compensation package includes:
- Non-qualified stock options to purchase 2,000 shares of common stock
- Restricted stock unit awards covering 7,288 shares
The stock options were granted at $33.55 per share, matching PRAX's closing price on the grant date. The options will vest over four years, with 25% vesting after the first year and the remainder monthly over three years. Restricted stock units will vest in four equal annual installments. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in five major investor conferences in March 2025:
- 45th Annual TD Cowen Health Care Conference in Boston (March 5, 9:10 AM EDT)
- Leerink Partners Global Healthcare Conference in Miami (March 10, 3:40 PM EDT)
- Jefferies Biotech on the Bay Summit in Miami (March 11)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 12, 2:30 PM EDT)
- UBS Virtual CNS Day (March 17, 9:30 AM EDT)
The company will present corporate overviews, participate in fireside chats, and offer one-on-one investor meetings. Live webcasts will be available for most events, with 90-day replay access through the company's website.
Praxis Precision Medicines (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) recommended stopping Study 1 of the Essential3 program for futility, as it's unlikely to meet primary efficacy endpoints. Despite this, Praxis will continue both Study 1 and 2 to completion, with topline results expected in Q3 2025.
The company provided updates on multiple pipeline programs including:
- Vormatrigine trials RADIANT and POWER1 for focal onset seizures with results expected in 2025
- Relutrigine development for epilepsies with EMERALD study initiation by mid-2025
- Elsunersen EMBRAVE3 trial for SCN2A-DEE starting mid-2025
Financial highlights show $469.5 million in cash and equivalents as of December 31, 2024, expected to fund operations into 2028. Q4 2024 net loss was $58.7 million, with full-year 2024 net loss at $182.8 million.
Praxis Precision Medicines (Nasdaq: PRAX) has announced new equity grants under its 2024 Inducement Plan. The company's Compensation Committee approved stock options to purchase 4,050 shares and restricted stock unit awards covering 3,038 shares for three new non-executive employees on February 3, 2025.
The stock options were granted at an exercise price of $80.26 per share, matching the closing price of Praxis' common stock on the grant date. The options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The restricted stock units will vest in four equal annual installments. These grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two upcoming investor conferences in February 2025.
The company will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference in New York City on February 6, 2025, at 2:30 p.m. EST, and at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST.
One-on-one meetings with investors will be available during both conferences through respective representatives. Live webcasts will be accessible through provided links and the company's website, with replays available for 90 days under the 'Events and Presentations' page in the 'Investors + Media' section.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
